F-group (family)
12.3.1.19 Gal_mutarotas_2
Ligands and drugs
354
Member domains
154
with ligand contacts (≤ 4 Å)
43.5% of members
128
with DrugDomain annotations
36.2% of members
79
with a DrugBank compound
22.3% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 12.3.1.19 belongs to X-group 12 Glycosyl hydrolase domain-like, which binds 6.5 ligand superclasses per 20 proteins, narrower than 68% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 10 |
| DB04807 | XTG | 4-NITROPHENYL-(6-S-ALPHA-D-XYLOPYRANOSYL)-BETA-D-GLUCOPYRANOSIDE | 6 |
| DB04878 | VOG | Voglibose | 5 |
| DB00491 | MIG | Miglitol | 4 |
| DB02379 | BGC | Beta-D-Glucose | 3 |
| DB00284 | — | — | 2 |
| DB03567 | A2G | alpha-N-Acetyl-D-galactosamine | 2 |
| DB00125 | ARG | Arginine | 1 |
| DB00419 | NBV | Miglustat | 1 |
| DB00747 | — | Scopolamine | 1 |
| DB01694 | TAR | D-tartaric acid | 1 |
| DB03206 | NOJ | Duvoglustat | 1 |
| DB03283 | FUL | beta-L-fucose | 1 |
| DB03389 | XYS | alpha-D-Xylopyranose | 1 |
| DB17804 | 6A9 | N-9-Methoxynonyldeoxynojirimycin | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 17 |
| CAmetal | CALCIUM ION | 11 |
| P6G | HEXAETHYLENE GLYCOL | 10 |
| CL | CHLORIDE ION | 7 |
| XTG | 4-NITROPHENYL 6-THIO-6-S-ALPHA-D-XYLOPYRANOSYL-BETA-D-GLUCOPYRANOSIDE | 6 |
| VOG | (1S,2S,3R,4S,5S)-5-[(1,3-dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol | 4 |
| KTL | (1S,2R,3R,4S)-1-{(1S)-2-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrothiophenium-1-yl]-1-hydroxyethyl}-2,3,4,5-tetrahydroxypentyl sulfate | 3 |
| A2G | 2-acetamido-2-deoxy-alpha-D-galactopyranose | 2 |
| BGC | beta-D-glucopyranose | 2 |
| NSQ | 4-nitrophenyl alpha-D-6-sulfoquinovoside | 2 |
| VND | (1S,2S,3R,4S,5S)-5-(butylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol | 2 |
| W9P | (1~{S},2~{S},3~{R},4~{S},5~{S})-1-(hydroxymethyl)-5-[6-[[2-[oxidanyl(oxidanylidene)-$l^{4}-azanyl]-4-(1,2,3,4-tetrazol-1-yl)phenyl]amino]hexylamino]cyclohexane-1,2,3,4-tetrol | 2 |
| W9V | (1S,2S,3R,4S,5S)-1-(hydroxymethyl)-5-{[(5Z)-6-{[2-nitro-4-(2H-1,2,3-triazol-2-yl)phenyl]amino}hex-5-en-1-yl]amino}cyclohexane-1,2,3,4-tetrol | 2 |
| W9Y | (1S,2S,3R,4S,5S)-1-(hydroxymethyl)-5-[(6-{[2-nitro-4-(1H-1,2,3-triazol-1-yl)phenyl]amino}hexyl)amino]cyclohexane-1,2,3,4-tetrol | 2 |
| WA7 | (1S,2S,3R,4S,5S)-1-(hydroxymethyl)-5-[(4-{[2-nitro-4-(triazan-1-yl)phenyl]amino}butyl)amino]cyclohexane-1,2,3,4-tetrol | 2 |
| X8Y | (1S,2S,3R,4S,5S)-5-({6-[(4-azido-2-nitrophenyl)amino]hexyl}amino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol | 2 |
| XOD | (1S,2S,3R,4S,5S)-1-(hydroxymethyl)-5-[(6-{[2-nitro-4-(pyrimidin-2-yl)phenyl]amino}hexyl)amino]cyclohexane-1,2,3,4-tetrol | 2 |
| 56I | [(1R,2R,3R,4R,5S)-2-(hydroxymethyl)-3,4,5-tris(oxidanyl)cyclohexyl]sulfamic acid | 1 |
| 66V | 1-(8-{[(1S,2R,3S,4S,5R,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)cyclohexyl]amino}octyl)triaza-1,2-dien-2-ium | 1 |
| 6A9 | N-9'-methoxynonyl-1-deoxynojirimycin | 1 |